Status and phase
Conditions
Treatments
About
Phase 3 placebo-controlled trial to determine efficacy of the probiotic LGG for reducing acute treatment related GI toxicity in patients with GI malignancy with phase 1 safety lead-in.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Current diagnosis of a gastrointestinal, abdominal, or pelvic cancer for which the use of continuous definitive or adjuvant external-beam RT to the abdomen or pelvis to a minimum dose of 4500 cGy is planned.
Scheduled to receive concurrent administration of fluoropyrimidine chemotherapy (5-FU or capecitabine) during radiation therapy.
Age ≥ 18 years.
Life expectancy ≥ 6 months.
Negative pregnancy test done ≤7 days prior to registration (for women of childbearing potential only).
The following laboratory values obtained ≤ 28 days prior to registration:
ECOG Performance Status (PS) of 0, 1, or 2.
Willingness to abstain from ingestion of yogurt products and/or any product containing probiotics during study drug treatment.
Ability to complete questionnaire(s) alone or with assistance.
Ability to understand and willingness to sign informed consent.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
23 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal